Core Insights - Merck reported $16.4 billion in revenue for Q4 2025, a 5% year-over-year increase, with an EPS of $2.04 compared to $1.72 a year ago, exceeding Zacks Consensus Estimates for both revenue and EPS [1] Financial Performance - Revenue surprise was +1.33% over the Zacks Consensus Estimate of $16.19 billion, while the EPS surprise was +0.62% over the consensus estimate of $2.03 [1] - Merck's shares returned +5.5% over the past month, outperforming the Zacks S&P 500 composite's +1.8% change [3] Key Product Sales - Hospital Acute Care (Bridion) in the U.S. generated $451 million, exceeding the estimated $418.39 million, reflecting an 18.1% year-over-year increase [4] - Oncology (Keytruda) international sales reached $3.45 billion, surpassing the $3.39 billion estimate, with a 15% year-over-year increase [4] - Diabetes (Janumet) in the U.S. reported $57 million, below the estimated $69.57 million, marking a significant decline of 37.4% year-over-year [4] - Oncology (Lynparza) alliance revenue in the U.S. was $180 million, slightly above the $176.62 million estimate, with a 1.7% year-over-year increase [4] - Cardiovascular (Winrevair) sales were $467 million, exceeding the estimated $452.86 million [4] - Vaccines (Vaxneuvance) generated $140 million, below the $178.52 million estimate, reflecting a 13% year-over-year decline [4] - Oncology (Welireg) sales reached $220 million, surpassing the $195.53 million estimate [4] - Oncology (Keytruda) domestic sales were $8.34 billion, slightly above the $8.31 billion estimate, with a 6.4% year-over-year increase [4] - Oncology (Lenvima) alliance revenue was $272 million, exceeding the $243.71 million estimate, with a 6.7% year-over-year increase [4] - Vaccines (Gardasil) reported $1.03 billion, close to the $1.04 billion estimate, but down 33.5% year-over-year [4] - Virology (Lagevrio) sales were $57 million, above the $45.95 million estimate, but down 52.9% year-over-year [4] - Oncology (Reblozyl) alliance revenue was $164 million, exceeding the $138.97 million estimate, with a significant 49.1% year-over-year increase [4]

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 1% on Tuesday.The Dow traded down 0.19% to 49,316.23 while the NASDAQ dipped 1.23% to 23,302.18. The S&P 500 also fell, dropping, 0.62% to 6,933.29.Check This Out: How To Earn $500 A Month From Goldman Sachs Stock Ahead Of Q4 EarningsLeading and Lagging SectorsMaterials shares gained by 1.8% on Tuesday.In trading on Tuesday, information technology stocks fell by 1.9%.Top HeadlineOn Tuesday, Pfizer Inc. (NYSE:PFE) sh ...

Investors with a lot of money to spend have taken a bullish stance on Pfizer (NYSE:PFE).And retail traders should know.We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with PFE, it often means somebody knows something is about to happen.So how do we know what these investors just did? Today, Benzinga's options scanner spotted 21 un ...

Company Performance - Pfizer Inc. reported fourth-quarter 2025 adjusted earnings of 66 cents, an increase from 63 cents a year ago, surpassing the consensus estimate of 57 cents [3] - Fourth-quarter sales for Pfizer fell 1% year over year to $17.56 billion, which was above the consensus estimate of $16.96 billion, reflecting an operational decline of 3% [3] Drug Development - Pfizer shared topline data from a mid-stage study for a weight loss drug, specifically the Phase 2b VESPER-3 study of monthly maintenance dosing of PF'3944 (MET-097i) in adults with obesity or overweight without type 2 diabetes [2]

Wegovy maker Novo Nordisk expects a decline in sales this year, it said on Tuesday as it reported fourth-quarter operating profit slightly above forecasts. ...

Core Insights - Novo Nordisk (NVO) announced positive top-line data from its late-stage REIMAGINE clinical study program for CagriSema, a next-generation treatment for type II diabetes (T2D) [1] Group 1: CagriSema Efficacy - CagriSema is a fixed-dose combination of cagrilintide (2.4 mg) and Wegovy (semaglutide 2.4 mg), showing superior HbA1c reduction and weight loss at week 68 compared to semaglutide across all tested doses [2] - In the phase III REIMAGINE 2 study, CagriSema demonstrated a 1.91 percentage-point reduction in HbA1c from a baseline of 8.2%, compared to a 1.76 percentage-point reduction with semaglutide [4] - Patients receiving the higher CagriSema dose achieved a 14.2% reduction in body weight from a mean baseline of 101 kg, compared to a 10.2% reduction with semaglutide [5] Group 2: Study Details - The phase III REIMAGINE 2 study involved 2,728 adults with T2D inadequately controlled with metformin, comparing two CagriSema doses against semaglutide and placebo [3] - Approximately 40% of participants were already using an SGLT2 inhibitor, providing insights into CagriSema's performance in common treatment backgrounds [3] Group 3: Safety Profile - CagriSema's safety profile was consistent with established incretin and amylin therapies, with mostly mild gastrointestinal events that tended to diminish over time [10] - The treatment regimen estimand analysis showed a superior HbA1c reduction of 1.80 percentage points and weight loss of 12.9% for CagriSema compared to semaglutide's 1.68 percentage points and 9.2% weight loss [9] Group 4: Future Development - Novo Nordisk is evaluating CagriSema in additional phase III studies for T2D and obesity, with plans to discuss regulatory pathways following positive data from the REIMAGINE and REDEFINE studies [11][12] - A regulatory application for CagriSema to reduce excess body weight is expected to be reviewed by the FDA in 2026 [13][14]

Financial Performance - Net sales for 2025 reached DKK 309,064 million, representing a 6% increase compared to 2024, and a 10% increase at constant exchange rates (CER) [2] - Operating profit decreased by 1% in Danish kroner to DKK 127,658 million, but increased by 6% at CER [2][4] - Net profit for 2025 was DKK 102,434 million, a 1% increase from DKK 100,988 million in 2024 [2] - Diluted earnings per share rose by 2% to DKK 23.03 from DKK 22.63 in 2024 [2] Market and Product Insights - Novo Nordisk achieved a 10% sales growth at CER, reaching nearly 46 million patients with its treatments despite a challenging year [3] - Sales in US Operations increased by 3% in Danish kroner and 8% at CER, while International Operations saw a 10% increase in Danish kroner and 14% at CER [4] - Sales in Obesity and Diabetes care grew by 7% in Danish kroner to DKK 289.5 billion, driven by a 26% increase in Obesity care and a 2% increase in GLP-1 diabetes sales [4] Future Outlook - Adjusted sales growth for 2026 is expected to be between -5% to -13% at CER, influenced by lower realized prices and increased competition [4] - The global GLP-1 market is anticipated to expand, with new treatments like the Wegovy pill expected to enhance patient reach [4] - The company plans to propose a final dividend of DKK 7.95 per share for 2025, totaling DKK 11.70 for the year, and initiate a new share repurchase program of up to DKK 15 billion [4]

Bagsværd, Denmark, 3 February 2026 – Novo Nordisk today announced sales and operating profit growth at constant exchange rates (CER) for 2025 and released the 2026 full-year sales and operating profit outlook at CER. 2025 sales and operating profit growth at CERIn 2025, Novo Nordisk’s sales increased by 10% and operating profit increased by 6%, compared to previously issued guidance of 8 to 11% sales growth and 4 to 7% operating profit growth1. Sales in US Operations were positively impacted by gross-to-net ...

Pfizer (NYSE: PFE) stock gave up 3.3% through 10:50 a.m. ET Tuesday despite delivering an earnings beat this morning. Analysts forecast the pharmaceuticals giant would earn $0.57 per share on $16.8 billion in Q4 sales. Pfizer actually earned $0.66 (adjusted for one-time items) on sales of $17.6 billion. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks » Image source: Getty Images. Pfizer ...

Group 1 - AstraZeneca PLC is recognized for its strong cancer franchise and is recommended to hold by Jim Cramer, who believes it has a better portfolio compared to AbbVie at this moment [1] - AstraZeneca is one of the largest pharmaceutical companies globally, focusing on oncology, cardiovascular, respiratory, and rare diseases, with a robust on-market portfolio and a leading late-stage pipeline [2] - The company is led by CEO Pascal Soriot, noted for his exceptional management and innovative culture, which is expected to drive strong growth in the future [2] Group 2 - Recent regulatory concerns in the United States have overshadowed AstraZeneca's strengths, creating an opportunity for investors to acquire shares below their intrinsic value [2]